

**ASX Announcement | 5 January 2024  
Vioneering Technologies, Inc. (ASX:VTI)**

**Placement of shortfall**

**Vioneering Technologies, Inc. (ASX: VTI)** ('Vioneering' or 'the **Company**'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, advises that it has issued a total of 1,084,843 CHESS Depositary Interests and shares of Class A Common Stock, forming part of the shortfall from the Company's recent non-renounceable rights offering (**Shortfall Securities**), to professional and sophisticated investors in Australia and other jurisdictions (including the United States). The Shortfall Securities were issued at A\$0.22 each (being the offer price under the rights offering) to raise a total of A\$238,665. The funds raised will be used for the same purposes as outlined in the Offer Booklet for the rights offering.

The Shortfall Securities issued to investors in the United States (being 432,115 shares of Class A Common Stock) will be subject to certain restrictions on transfer under applicable U.S. securities laws.

The remaining shortfall is 5,759,173 Shortfall Securities. The Company may place the balance of the Shortfall Securities by 6 February 2024 (being within 3 months after the rights offering closing date of 6 November 2023). Please refer to the Offer Booklet for further details on the issue of the shortfall.

**Ends**

**This release was authorized by the CEO, Dr. Juan Carlos Aragón.**

**For more information, please contact:**

<b><i>Company</i></b>	<b><i>Investor and media relations</i></b>
Brian Lane COO and CFO, Vioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

**About Vioneering Technologies**

Vioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtivision.com](http://www.vtivision.com) or call +1 844-884-5367, ext. 104.

**Foreign ownership restrictions**

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US'

designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.